publication date: Apr. 30, 2015

Circulating Tumor Cells can be Used to Detect DLBCL Recurrence, Researchers Say

 

Researchers at NCI found that measurement of circulating tumor DNA in blood can be used to detect disease recurrence in patients with diffuse large B-cell lymphoma.

In most patients, measurement of ctDNA enabled detection of microscopic disease before it could be seen on CT scans, which is the current standard for disease assessment. Monitoring for recurrence by testing blood samples may reduce the need for multiple CT scans that increase a patient’s exposure to radiation and add to health care costs, researchers said. The research was published in Lancet Oncology.

NCI investigators in the Center for Cancer Research analyzed serum from 126 patients with DLBCL for the presence of ctDNA. To detect ctDNA in serum, the researchers used a quantitative method that assesses gene segments with advanced sequencing techniques.

All patients received therapy involving the drugs etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, known as EPOCH, with or without the biologic agent rituximab, in clinical trials between May 1993 and December 2013. Serum samples were collected before treatment, during treatment, and for many years after therapy.

The patients also had CT scans done at the same time as the blood testing as part of standard surveillance. They were followed for a median of 11 years after the completion of therapy.

Results of this study showed that, … Continue reading CCL April – Circulating Tumor Cells can be Used to Detect DLBCL Recurrence, Researchers Say

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.